全文获取类型
收费全文 | 2051351篇 |
免费 | 158701篇 |
国内免费 | 7653篇 |
专业分类
耳鼻咽喉 | 27314篇 |
儿科学 | 66258篇 |
妇产科学 | 57006篇 |
基础医学 | 284704篇 |
口腔科学 | 56489篇 |
临床医学 | 180574篇 |
内科学 | 416691篇 |
皮肤病学 | 46886篇 |
神经病学 | 166986篇 |
特种医学 | 83752篇 |
外国民族医学 | 596篇 |
外科学 | 321550篇 |
综合类 | 46993篇 |
现状与发展 | 2篇 |
一般理论 | 636篇 |
预防医学 | 159539篇 |
眼科学 | 44903篇 |
药学 | 145357篇 |
5篇 | |
中国医学 | 3723篇 |
肿瘤学 | 107741篇 |
出版年
2018年 | 20472篇 |
2016年 | 18551篇 |
2015年 | 20974篇 |
2014年 | 29626篇 |
2013年 | 44895篇 |
2012年 | 56855篇 |
2011年 | 60804篇 |
2010年 | 37683篇 |
2009年 | 36425篇 |
2008年 | 57376篇 |
2007年 | 61298篇 |
2006年 | 62316篇 |
2005年 | 60741篇 |
2004年 | 57969篇 |
2003年 | 56417篇 |
2002年 | 54282篇 |
2001年 | 96557篇 |
2000年 | 99479篇 |
1999年 | 83660篇 |
1998年 | 24516篇 |
1997年 | 22108篇 |
1996年 | 22822篇 |
1995年 | 22451篇 |
1994年 | 21100篇 |
1993年 | 19747篇 |
1992年 | 68217篇 |
1991年 | 65949篇 |
1990年 | 63904篇 |
1989年 | 61048篇 |
1988年 | 56682篇 |
1987年 | 55644篇 |
1986年 | 52892篇 |
1985年 | 50831篇 |
1984年 | 38576篇 |
1983年 | 32616篇 |
1982年 | 20159篇 |
1981年 | 17925篇 |
1980年 | 16977篇 |
1979年 | 35031篇 |
1978年 | 25121篇 |
1977年 | 21192篇 |
1976年 | 19661篇 |
1975年 | 20956篇 |
1974年 | 24828篇 |
1973年 | 23699篇 |
1972年 | 22233篇 |
1971年 | 20486篇 |
1970年 | 19007篇 |
1969年 | 17897篇 |
1968年 | 16841篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
55.
P E Santos E Piontelli Y R Shea M L Galluzzo S M Holland M E Zelazko S D Rosenzweig 《Medical mycology》2006,44(8):749-753
Infections due to Penicillium species other than P.marneffei are rare. We identified a boy with X-linked chronic granulomatous disease (X-CGD) with a pulmonary nodule and adjacent rib osteomyelitis caused by Penicillium piceum. The only sign of infection was an elevated sedimentation rate. P. piceum was isolated by fine needle aspirate and from excised infected tissues. Surgical removal and one year of voriconazole treatment were very well tolerated and led to complete recovery. Microbiological, microscopic and molecular studies support the fungal diagnosis. P. piceum should be considered as a relevant pathogen in immunocompromised patients. 相似文献
56.
Christine E. East Fung Yee Chan Shaun P. Brennecke James F. King Paul B. Colditz 《分娩》2006,33(2):101-109
Abstract: Background: Fetal pulse oximetry improves the assessment of fetal well‐being during labor. The objective of this study was to evaluate women's satisfaction with their experience with this additional technology. Methods: We surveyed women participating in the FOREMOST trial, a randomized controlled trial comparing the addition of fetal pulse oximetry (FPO) to conventional cardiotocograph (CTG) monitoring (intervention group), versus CTG‐only (control group), in the presence of nonreassuring fetal status during labor. Our survey evaluated 3 aspects of women's experience: labor, fetal monitoring, and participation in the research. The survey was administered within a few days of giving birth and repeated 3 months later. Results: No differences were found between the intervention and control groups for women's evaluations of their labor, fetal monitoring, research, or overall experiences when surveyed on both occasions. Within each study group, a small but statistically significant decline occurred in women's scores for their experience of labor and overall experience from the initial survey close to the time of giving birth, to 3 months later. The magnitude of differences in responses over time was similar for the both groups. Women were more satisfied after a spontaneous or assisted vaginal birth than after cesarean section. Length of time the research midwife was present had a significant positive effect on women's ratings of their experience several days after giving birth (p = 0.006), but no effect at 3 months. Conclusions: The addition of fetal pulse oximetry for the assessment of fetal well‐being during labor did not affect childbearing women's perceptions of fetal monitoring or their labor. Women evaluated their experience in the research process positively overall. Small changes occurred in women's perception of their satisfaction over time. (BIRTH 33:2 June 2006) 相似文献
57.
58.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
59.
60.